The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial

被引:88
作者
Tong, X. L. [1 ]
Wu, S. T. [2 ]
Lian, F. M. [1 ]
Zhao, M. [3 ]
Zhou, S. P. [3 ]
Chen, X. Y. [1 ]
Yu, B. [1 ]
Zhen, Z. [1 ]
Qi, L. W. [4 ]
Li, P. [4 ]
Wang, C. Z. [5 ]
Sun, H. [3 ,6 ]
Yuan, C. S. [5 ]
机构
[1] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China
[3] Tasly Pharmaceut Co Ltd, Tianjin, Peoples R China
[4] China Pharmaceut Univ, Nanjing 210009, Jiangsu, Peoples R China
[5] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[6] Tianjin Univ, Tianjin 300072, Peoples R China
关键词
Chinese medicine; FPG; HbA1c; HOMA-IR; HOMA-; Rhizoma Coptidis; Tang-Min-Ling-Wan or TM81; type; 2; diabetes; BERBERINE; GLUCOSE; OUTCOMES;
D O I
10.1111/dom.12051
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Aim TM81 (or Tang-Min-Ling-Wan) is a Chinese medicine. Previous studies suggested that this medicine is effective for treating type 2 diabetes. This controlled trial evaluated the safety and effectiveness of TM81 in the treatment of type 2 diabetic patients. Methods This study was a large-scale controlled clinical trial to evaluate the safety and effectiveness of TM81 on type 2 diabetes. After a 2-week run-in period, 480 overweight type 2 early-stage diabetic patients [3565years old, HbA1c 7.0%, fasting plasma glucose (FPG) 7.013.9mM or 2h plasma glucose (PG)>11.1mM, body mass index (BMI)24kg/m2] were enrolled. These patients were divided into a TM81 group and placebo group in a 3:1 ratio. The subjects received 6g TM81 or placebo, three times daily for 12weeks. Results After treatment, the HbA1c decrease was 1.02% in the TM81 group versus 0.47% in the placebo group. The FPG decreased 0.8 +/- 0.1 mM in the TM81 group versus an increase of 0.2 +/- 0.2mM in the placebo group. The PG decreased 2.7 +/- 0.3 mM in the TM81 group versus a decrease of 0.9 +/- 0.4 mM in the placebo group (all p<0.05). The TM81 was more effective for patients with higher baseline HbA1c levels. The TM81 group also showed improved -cell function and increased homeostatic model assessment (HOMA)-. In addition, body weight, BMI and waist circumference of subjects in the TM81 group were reduced, and the symptoms related to diabetes were improved. There were no significant differences in the types and frequency of adverse reactions between the two groups. Conclusions The data showed that TM81 is effective in controlling blood glucose level and is safe to use in patients with early-stage type 2 diabetes.
引用
收藏
页码:448 / 454
页数:7
相关论文
共 23 条
[1]
Hypoglycemic and Hypolipidemic Effects of Hesperidin and Cyclodextrin-Clathrated Hesperetin in Goto-Kakizaki Rats with Type 2 Diabetes [J].
Akiyama, Satoko ;
Katsumata, Shin-ichi ;
Suzuki, Kazuharu ;
Nakaya, Yumi ;
Ishimi, Yoshiko ;
Uehara, Mariko .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2009, 73 (12) :2779-2782
[2]
Blood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial [J].
Anderson, Robert J. ;
Bahn, Gideon D. ;
Moritz, Thomas E. ;
Kaufman, Derrick ;
Abraira, Carlos ;
Duckworth, William .
DIABETES CARE, 2011, 34 (01) :34-38
[3]
[Anonymous], 1999, DIAGN CLASS DIAB MEL
[4]
Bennett WL, 2011, ORAL DIABETES MED AD
[5]
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants [J].
Danaei, Goodarz ;
Finucane, Mariel M. ;
Lu, Yuan ;
Singh, Gitanjali M. ;
Cowan, Melanie J. ;
Paciorek, Christopher J. ;
Lin, John K. ;
Farzadfar, Farshad ;
Khang, Young-Ho ;
Stevens, Gretchen A. ;
Rao, Mayuree ;
Ali, Mohammed K. ;
Riley, Leanne M. ;
Robinson, Carolyn A. ;
Ezzati, Majid .
LANCET, 2011, 378 (9785) :31-40
[6]
Weight and Metabolic Outcomes After 2 Years on a Low-Carbohydrate Versus Low-Fat Diet A Randomized Trial [J].
Foster, Gary D. ;
Wyatt, Holly R. ;
Hill, James O. ;
Makris, Angela P. ;
Rosenbaum, Diane L. ;
Brill, Carrie ;
Stein, Richard I. ;
Mohammed, B. Selma ;
Miller, Bernard ;
Rader, Daniel J. ;
Zemel, Babette ;
Wadden, Thomas A. ;
Tenhave, Thomas ;
Newcomb, Craig W. ;
Klein, Samuel .
ANNALS OF INTERNAL MEDICINE, 2010, 153 (03) :147-U37
[7]
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes [J].
Hanefeld, Markolf ;
Herman, Gary A. ;
Wu, Mei ;
Mickel, Carolyn ;
Sanchez, Matilde ;
Stein, Peter P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) :1329-1339
[8]
Li Bo, 2008, Yaoxue Xuebao, V43, P773
[9]
Antihyperglycemic Effects of Baicalin on Streptozotocin - Nicotinamide induced Diabetic Rats [J].
Li, Huan-Ting ;
Wu, Xiao-Dong ;
Davey, Andrew K. ;
Wang, Jiping .
PHYTOTHERAPY RESEARCH, 2011, 25 (02) :189-194
[10]
Mohan Maruga Raja Muthu Kumaradoss, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P510, DOI 10.3736/jcim20100602